The inefficiency of mTOR inhibitors may be related to lower dosing in the clinical ADPKD setting as compared to experimental conditions, since these drugs may cause serious systemic adverse effects (149). This evidence concerns the gene MTOR and autosomal dominant polycystic kidney disease.